diagens.comCrawled Nov 6, 2026
Hangzhou Desheng Biotechnology Co., Ltd. (listed as Desheng Technology, stock code 02526.HK) is a listed company specializing in AI medical imaging, offering AI karyotyping analysis systems, the iMedImage medical imaging large model, the iMed MaaS platform, and automated solutions for cellular genetics labs.
The Hong Kong Polytechnic University (PolyU) and Diagens Tech are collaborating to launch a joint laboratory dedicated to advancing AI-driven medical innovation. The initiative focuses on developing and translating general AI applications for healthcare purposes, aiming to enhance medical diagnostics and treatment methods.
Sep 2026The Hong Kong Polytechnic UniversityNews article
Hangzhou Diagens Biotechnology secures China’s first **Class III approval** for its **AI-powered karyotype analysis software**, *AutoVision*. The tool automates chromosome imaging diagnostics, aiding genetic disorder detection. Regulatory clearance covers its use in clinical settings under China’s National Medical Products Administration.
May 2026Yahoo FinanceNews article
Hangzhou Diagens Biotechnology secures **NMPA Category III approval** for its **AI AutoVision platform**, an intelligent system for automated chromosome karyotyping. The approval enables commercialization of its AI-driven genetic diagnostics solution in China. The company now advances its position in AI-powered medical diagnostics.
May 2026Fineline CubeNews article
Diagens transitions from technical validation to commercialization, achieving **RMB 164 million in annual revenue**—a **133.7% year-on-year increase**—by leveraging its **100-billion-parameter AI model** for medical applications. Licensing agreements now drive the company’s growth, marking a shift toward scalable revenue streams. The company highlights its progress in deploying advanced AI solutions for healthcare diagnostics and treatment optimization.
Apr 2026PR NewswireNews article
